Advertisement
Research Article| Volume 1, ISSUE 3, P467-478, September 1981

Therapeutic Drug Monitoring: Pharmacokinetic and Pharmacodynamic Principles

  • Joan H. Howanitz
    Correspondence
    Corresponding author: Division of Clinical Pathology, Department of Pathology, State University of New York, Upstate Medical Center, 750 East Adams Street, Syracuse, New York 13210
    Affiliations
    Assistant Professor of Pathology, State University of New York, Upstate Medical Center College of Medicine, Syracuse, New York

    Assisant Director of Clinical Pathology, University Hospital of Upstate Medical Center, Syracuse, New York
    Search for articles by this author
  • Peter J. Howanitz
    Affiliations
    Assistant Professor of Pathology, State University of New York, Upstate Medical Center College of Medicine, Syracuse, New York

    Assistant Director of Clinical Pathology, University Hospital of Upstate Medical Center, Syracuse, New York
    Search for articles by this author
DOI:https://doi.org/10.1016/S0272-2712(18)31085-0
Therapeutic Drug Monitoring: Pharmacokinetic and Pharmacodynamic Principles
Previous ArticleInstrumentation and Techniques For Therapeutic Drug Monitoring
Next ArticleAntiepileptic Therapeutic Drug Monitoring
      This paper is only available as a PDF. To read, Please Download here.
      The individualization of drug dosage is desirable as each patient varies in his response to a prescribed dose. Factors that should be considered in the interpretation of serum drug concentrations and in the adjustment of standard doses include compliance, bioavailability, drug pharmacokinetics, physiologic and genetic factors, intercurrent disease, and drug interactions.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Aranda J.V.
        • Türmen R.
        • Cote-Boileau T.
        Drug monitoring in the perinatal patient: Uses and abuses.
        Ther. Drug Monitor. 1980; 2: 39
        • Bennett W.M.
        • Muther R.S.
        • Parker R.A.
        • et al.
        Drug therapy in renal failure: Dosing guidelines for adults.
        Ann. Intern. Med. 1980; 93: 286
        • Gillette J.R.
        • Davis D.C.
        • Sasame H.A.
        Cytochrome P-450 and its role in drug metabolism.
        Annu. Rev. Pharmacol. 1972; 12: 57
        • Greenblatt D.J.
        • Koch-Weser J.
        Clinical pharmacokinetics (first of two parts).
        N. Engl. J. Med. 1975; 293: 702
        • Greenblatt D.J.
        • Koch-Weser J.
        Clinical pharmacokinetics (second of two parts).
        N. Engl. J. Med. 1975; 293: 964

      6. Ireland, G.: Clinical pharmacokinetics. American Association for Clinical Chemistry, Therapeutic Drug Monitoring Manual, 1979

        • Jellett L.B.
        Plasma concentration in the control of drug therapy.
        Drugs. 1976; 11: 412
        • Johnston G.D.
        • Kelly J.G.
        • McDevitt D.G.
        Do patients take digoxin?.
        Br. Heart J. 1978; 40: 1
        • Koch-Weser J.
        Serum concentration of drugs as guides to pharmacotherapy.
        Excerpta Medica. 1980; 501: 3
        • Koch-Weser J.
        Serum drug concentrations of therapeutic guides.
        N. Engl. J. Med. 1972; 287: 227

      11. Pippenger, C. E.: Drug protein binding: An overview. American Association for Clinical Chemistry, Therapeutic Drug Monitoring Manual, 1979

        • Richens A.
        • Warrington S.
        When should plasma drug levels be monitored?.
        Drugs. 1979; 17: 488
        • Rowland M.
        Plasma protein binding and therapeutic drug monitoring.
        Ther. Drug Monitor. 1980; 2: 29
        • Shirkey H.C.
        Pediatric clinical pharmacology and therapeutics.
        in: Avery G.S. Drug Treatment Principles and Practice of Clinical Pharmacology and Therapeutics. ADIS Press, Sidney1980: 98
        • Sjoqvist F.
        • Borga O.
        • L’Orme M.
        Fundamentals of clinical pharmacology.
        in: Avery G.S. Drug Treatment Principles and Practice of Clinical Pharmacology and Therapeutics. ADIS Press, Sidney1980: 1
        • Ueda C.T.
        • Dzindzio B.S.
        Quinidine kinetics in congestive heart failure.
        Clin. Pharmacol. Ther. 1978; 23: 158
        • Van der Kleijn E.
        • Baars A.M.
        • Damsma K.E.
        • et al.
        Pharmacokinetic interpretation of the fate of drugs in body fluids.
        Excerpta Medica. 1980; 501: 18
        • Welling P.G.
        How food and fluid affect drug absorption.
        Postgrad. Med. 1977; 62: 73
        • Werner M.
        Management of apparently inappropriate therapeutic drug monitoring data.
        Lab. Med. 1980; 11: 818

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0272-2712(18)31085-0

      Copyright

      © 1981 Elsevier Inc. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX